Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000160679 | SCV000211294 | uncertain significance | not provided | 2018-12-11 | criteria provided, single submitter | clinical testing | This variant is denoted MSH6 c.2260A>C at the cDNA level, p.Thr754Pro (T754P) at the protein level, and results in the change of a Threonine to a Proline (ACT>CCT). This variant was observed in at least one individual diagnosed with breast cancer (Lu 2015). MSH6 Thr754Pro was not observed at a significant allele frequency in large population cohorts (Lek 2016). MSH6 Thr754Pro is located in the Lever domain (Warren 2007, Kansikas 2011). In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available information, it is unclear whether MSH6 Thr754Pro is pathogenic or benign. We consider it to be a variant of uncertain significance. |
Color Diagnostics, |
RCV000772630 | SCV000905824 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-11-11 | criteria provided, single submitter | clinical testing | This missense variant replaces threonine with proline at codon 754 of the MSH6 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 29684080). This variant has been identified in 2/251058 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Labcorp Genetics |
RCV000821022 | SCV000961761 | benign | Hereditary nonpolyposis colorectal neoplasms | 2023-10-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000772630 | SCV001175745 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-08-05 | criteria provided, single submitter | clinical testing | The c.2260A>C (p.T754P) alteration is located in exon 4 (coding exon 4) of the MSH6 gene. This alteration results from a A to C substitution at nucleotide position 2260, causing the threonine (T) at amino acid position 754 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
All of Us Research Program, |
RCV003998496 | SCV004841916 | uncertain significance | Lynch syndrome | 2023-10-23 | criteria provided, single submitter | clinical testing | This missense variant replaces threonine with proline at codon 754 of the MSH6 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 29684080). This variant has been identified in 2/251058 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000160679 | SCV005623434 | uncertain significance | not provided | 2023-09-27 | criteria provided, single submitter | clinical testing |